Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Assessing tumor response to therapy.

Wolfgang A Weber¹

¹Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany. Wolfgang.weber@uniklinik-freiburg.de

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|April 22, 2009

Summary

This summary is machine-generated.

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026

Same author

Impact of different PSMA PET-based eligibility criteria on outcome of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy using [<sup>18</sup>F]rhPSMA-7/[<sup>18</sup>F]rhPSMA-7.3 (Flotufolastat).

EJNMMI research·2026

Same author

The role of 18F-FDG PET/CT in spinal infections: A comprehensive diagnostic tool.

Brain & spine·2026

Same author

Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy.

European journal of nuclear medicine and molecular imaging·2026

Same author

Value of a repeat <sup>18</sup>F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy.

European journal of nuclear medicine and molecular imaging·2026

Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

See all related articles

Computed Tomography (CT) has limitations in assessing anticancer drug efficacy. Positron Emission Tomography (PET) with 18F-FDG shows promise for earlier and more accurate tumor response assessment, especially in solid tumors.

Area of Science:

Oncology
Radiology
Nuclear Medicine

Background:

Current anticancer drug efficacy prediction is limited, relying on Computed Tomography (CT) for tumor response assessment.
CT faces challenges including interobserver variability, difficulty differentiating viable tumor from necrotic tissue, and limitations in assessing tumors that do not change in size.

Purpose of the Study:

To evaluate the potential of molecular imaging, specifically 18F-FDG Positron Emission Tomography (PET), to improve tumor response assessment compared to CT.
To highlight the need for standardized criteria for 18F-FDG PET in solid tumor response evaluation.

Main Methods:

Review of existing literature on tumor response assessment techniques.
Comparison of CT-based measurements with molecular imaging (18F-FDG PET) findings in various tumor types.

Related Experiment Videos

Last Updated: Jun 23, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Analysis of revised international criteria for malignant lymphoma incorporating 18F-FDG PET.

Main Results:

18F-FDG PET has demonstrated improved response assessment in malignant lymphoma, with its signal playing a central role in revised criteria.
Single-center studies suggest 18F-FDG PET offers earlier and more accurate tumor response assessment than CT in several solid tumors.
CT's limitations include underestimating response, overestimating treatment effects due to rapid regrowth, and inability to characterize non-changing tumors.

Conclusions:

18F-FDG PET holds significant potential for personalizing cancer treatment by providing more accurate tumor response data.
The absence of generally accepted international guidelines for 18F-FDG PET in solid tumors hinders comparative research and widespread adoption.
Development of international guidelines for 18F-FDG PET response assessment in solid tumors is crucial for advancing personalized oncology.